The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...